

M E M O R A N D U M

Thomas L. Williams, MD
Medical Director

Laura J. Brock
Service Executive

Deborah A. Perry, MD
Alan G. Torelli, MD
Diana L. Nevins, MD
Gregory S. Smith, MD
Gene N. Herbek, MD
John D. Gentry, MD
Christine P. Hans, MD
Shane K. Kohl, MD
Jiri B. Bedrnicek, MD
Tess A. Karre, MD
Charles H. Mosher, MD

TO: ONCOLOGIC PHYSICIANS
FROM: Tom Williams, M.D. – Methodist Pathology Center
RE: Estradiol Cross Reactivity with Fulvestrant (Faslodex)
DATE: May 2, 2016

We have been informed by our instrument vendor, Roche Diagnostics Corporation, that our estradiol assay demonstrates significant cross reactivity with the medication, Fulvestrant.

What this means is that the assay “sees” Fulvestrant to a degree, as estradiol. Thus, a patient receiving the medication will demonstrate a falsely elevated estradiol result with our assay.

There is a suitable estradiol assay available which does not suffer this interference, estradiol by tandem mass spectrometry ARUP test number 0093247. This can be ordered as “estradiol to ARUP #0093247”. In Cerner, this is an Unlisted Test order.

This estradiol method is also preferred for post-menopausal women due to its better chemical sensitivity and accuracy at low estradiol levels prevalent in this population. This reference laboratory test charge is somewhat more expensive, but remains within the range of charges for common laboratory tests.

Please contact Tom Williams, M.D. (402)354-4559 if you have questions.

Sincerely,



Dr. Tom Williams, Methodist Pathology Center

TW/hf